1733 related articles for article (PubMed ID: 25201530)
1. Organoid cultures derived from patients with advanced prostate cancer.
Gao D; Vela I; Sboner A; Iaquinta PJ; Karthaus WR; Gopalan A; Dowling C; Wanjala JN; Undvall EA; Arora VK; Wongvipat J; Kossai M; Ramazanoglu S; Barboza LP; Di W; Cao Z; Zhang QF; Sirota I; Ran L; MacDonald TY; Beltran H; Mosquera JM; Touijer KA; Scardino PT; Laudone VP; Curtis KR; Rathkopf DE; Morris MJ; Danila DC; Slovin SF; Solomon SB; Eastham JA; Chi P; Carver B; Rubin MA; Scher HI; Clevers H; Sawyers CL; Chen Y
Cell; 2014 Sep; 159(1):176-187. PubMed ID: 25201530
[TBL] [Abstract][Full Text] [Related]
2. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived xenografts and organoids model therapy response in prostate cancer.
Karkampouna S; La Manna F; Benjak A; Kiener M; De Menna M; Zoni E; Grosjean J; Klima I; Garofoli A; Bolis M; Vallerga A; Theurillat JP; De Filippo MR; Genitsch V; Keller D; Booij TH; Stirnimann CU; Eng K; Sboner A; Ng CKY; Piscuoglio S; Gray PC; Spahn M; Rubin MA; Thalmann GN; Kruithof-de Julio M
Nat Commun; 2021 Feb; 12(1):1117. PubMed ID: 33602919
[TBL] [Abstract][Full Text] [Related]
4. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.
Servant R; Garioni M; Vlajnic T; Blind M; Pueschel H; Müller DC; Zellweger T; Templeton AJ; Garofoli A; Maletti S; Piscuoglio S; Rubin MA; Seifert H; Rentsch CA; Bubendorf L; Le Magnen C
J Pathol; 2021 Aug; 254(5):543-555. PubMed ID: 33934365
[TBL] [Abstract][Full Text] [Related]
6. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
[No Abstract] [Full Text] [Related]
7. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J
Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514
[TBL] [Abstract][Full Text] [Related]
8. Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts.
Lee S; Burner DN; Mendoza TR; Muldong MT; Arreola C; Wu CN; Cacalano NA; Kulidjian AA; Kane CJ; Jamieson CAM
J Vis Exp; 2020 Feb; (156):. PubMed ID: 32065165
[TBL] [Abstract][Full Text] [Related]
9. High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.
Choo N; Ramm S; Luu J; Winter JM; Selth LA; Dwyer AR; Frydenberg M; Grummet J; Sandhu S; Hickey TE; Tilley WD; Taylor RA; Risbridger GP; Lawrence MG; Simpson KJ
SLAS Discov; 2021 Oct; 26(9):1107-1124. PubMed ID: 34111999
[TBL] [Abstract][Full Text] [Related]
10. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
Cao J; Chan WC; Chow MSS
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
[TBL] [Abstract][Full Text] [Related]
11. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
[No Abstract] [Full Text] [Related]
12. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models.
Risbridger GP; Toivanen R; Taylor RA
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29311126
[TBL] [Abstract][Full Text] [Related]
15. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.
Weeber F; van de Wetering M; Hoogstraat M; Dijkstra KK; Krijgsman O; Kuilman T; Gadellaa-van Hooijdonk CG; van der Velden DL; Peeper DS; Cuppen EP; Vries RG; Clevers H; Voest EE
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13308-11. PubMed ID: 26460009
[TBL] [Abstract][Full Text] [Related]
16. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.
Deplus R; Delliaux C; Marchand N; Flourens A; Vanpouille N; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncotarget; 2017 Feb; 8(7):11827-11840. PubMed ID: 28055969
[TBL] [Abstract][Full Text] [Related]
18. Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer.
Wadosky KM; Wang Y; Zhang X; Goodrich DW
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31259888
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.
Nitschke K; Erben P; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Wahby S; Nuhn P; Boutros M; Michel MS; von Hardenberg J; Worst TS
World J Urol; 2020 Mar; 38(3):637-645. PubMed ID: 30701334
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells.
Usui T; Sakurai M; Nishikawa S; Umata K; Nemoto Y; Haraguchi T; Itamoto K; Mizuno T; Noguchi S; Mori T; Iwai S; Nakagawa T; Yamawaki H; Ohama T; Sato K
Cancer Sci; 2017 Dec; 108(12):2383-2392. PubMed ID: 29024204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
